| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SHH |
| Uniprot No | Q15465 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-197aa |
| 氨基酸序列 | CGPGRGFGKRRHPKKLTPLAYKQFIPNVAEKTLGASGRYEGKISRNSERF KELTPNYNPDIIFKDEENTGADRLMTQRCKDKLNALAISVMNQWPGVKLR VTEGWDEDGHHSEESLHYEGRAVDITTSDRDRSKYGMLARLAVEAGFDWV YYESKAHIHCSVKAENSVAAKSGG |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SHH重组蛋白的参考文献示例：
1. **文献名称**：*Production and Purification of Recombinant Sonic Hedgehog (SHH) for In Vitro Studies*
**作者**：Lee, J. et al.
**摘要**：该研究描述了一种在大肠杆菌中高效表达并纯化重组SHH蛋白的方法，通过体外细胞实验验证其激活Hedgehog信号通路的能力，证实其可诱导神经元前体细胞分化。
2. **文献名称**：*Recombinant SHH Protein Enhances Bone Regeneration in a Mouse Model*
**作者**：Zhang, Y. et al.
**摘要**：研究利用哺乳动物细胞表达系统制备重组SHH蛋白，发现其在小鼠颅骨缺损模型中显著促进骨组织修复，机制可能与激活成骨细胞分化相关信号通路有关。
3. **文献名称**：*Structural and Functional Analysis of Engineered SHH Mutants*
**作者**：Smith, R.P. et al.
**摘要**：通过定点突变技术构建SHH重组蛋白变体，解析其晶体结构并评估生物活性，揭示了特定结构域在结合受体Patched1中的关键作用，为靶向药物设计提供依据。
(注：以上文献为示例，实际引用时需核实真实出版物信息。)
**Background of SHH Recombinant Protein**
The Sonic Hedgehog (SHH) protein is a critical morphogen in embryonic development, playing a central role in cell differentiation, tissue patterning, and organogenesis. It is a secreted glycoprotein belonging to the Hedgehog (Hh) signaling family, initially identified in *Drosophila*. SHH regulates key processes, including neural tube formation, limb bud development, and stem cell maintenance, by binding to the Patched (PTCH1) receptor, thereby activating the Smoothened (SMO)-mediated signaling cascade.
Recombinant SHH protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification to ensure bioactivity. Its production addresses the need for standardized, high-purity SHH for research and therapeutic applications. Unlike native SHH, recombinant forms allow precise control over post-translational modifications (e.g., cholesterol or palmitoyl groups), which influence its stability and signaling range.
SHH dysregulation is linked to developmental disorders (e.g., holoprosencephaly) and cancers (e.g., medulloblastoma, basal cell carcinoma). Recombinant SHH enables studies on SHH pathway mechanisms, drug screening for inhibitors (e.g., vismodegib), and tissue engineering. It also holds potential in regenerative medicine, such as promoting neuronal or pancreatic cell regeneration.
However, challenges remain, including optimizing delivery systems and minimizing off-target effects. Research continues to refine SHH-based therapies, balancing its potent morphogenic activity with clinical safety. Overall, SHH recombinant protein serves as a vital tool for developmental biology and translational medicine.
(Word count: 199)
×
